Osteosarcopenia as a Predictor of Histopathologic Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer: a Retrospective Cohort Study.

IF 2.1 3区医学 Q2 SURGERY

Langenbeck's Archives of Surgery Pub Date : 2025-03-25 DOI:10.1007/s00423-025-03687-8

Yuki Hirase, Ken Sasaki, Yusuke Tsuruda, Masataka Shimonosono, Yasuto Uchikado, Daisuke Matsushita, Takaaki Arigami, Nobuhiro Tada, Kenji Baba, Yota Kawasaki, Takao Ohtsuka

{"title":"Osteosarcopenia as a Predictor of Histopathologic Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer: a Retrospective Cohort Study.","authors":"Yuki Hirase, Ken Sasaki, Yusuke Tsuruda, Masataka Shimonosono, Yasuto Uchikado, Daisuke Matsushita, Takaaki Arigami, Nobuhiro Tada, Kenji Baba, Yota Kawasaki, Takao Ohtsuka","doi":"10.1007/s00423-025-03687-8","DOIUrl":null,"url":null,"abstract":"Purpose: Predicting chemoradiotherapy (CRT) response in esophageal cancer is essential as outcomes vary among patients. This study aimed to evaluate the impact of osteosarcopenia on the effectiveness of neoadjuvant CRT (NACRT).Methods: Ninety-five patients with advanced esophageal cancer who underwent surgical resection post-NACRT were included. Sarcopenia and osteopenia were determined using pre-NACRT skeletal muscle index and bone density at L3 and Th11 levels. Patients were categorized based on osteosarcopenia status.Results: Thirty-seven patients (39%) had osteosarcopenia. Among tumors, 49 (51.6%) were grade 1 (non-responders), 12 (12.6%) were grade 2, and 34 (35.8%) were grade 3 (responders). NACRT was significantly more effective in patients with above-median body mass index, shallow tumor depth, low squamous cell carcinoma antigen levels, and without osteosarcopenia. Osteosarcopenia was independently correlated with the histopathologic response to NACRT. No significant differences in overall or relapse-free survival were observed based on osteosarcopenia status.Conclusion: Osteosarcopenia may predict NACRT response in esophageal cancer.","PeriodicalId":17983,"journal":{"name":"Langenbeck's Archives of Surgery","volume":"410 1","pages":"105"},"PeriodicalIF":2.1000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11937212/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Langenbeck's Archives of Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00423-025-03687-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Predicting chemoradiotherapy (CRT) response in esophageal cancer is essential as outcomes vary among patients. This study aimed to evaluate the impact of osteosarcopenia on the effectiveness of neoadjuvant CRT (NACRT).

Methods: Ninety-five patients with advanced esophageal cancer who underwent surgical resection post-NACRT were included. Sarcopenia and osteopenia were determined using pre-NACRT skeletal muscle index and bone density at L3 and Th11 levels. Patients were categorized based on osteosarcopenia status.

Results: Thirty-seven patients (39%) had osteosarcopenia. Among tumors, 49 (51.6%) were grade 1 (non-responders), 12 (12.6%) were grade 2, and 34 (35.8%) were grade 3 (responders). NACRT was significantly more effective in patients with above-median body mass index, shallow tumor depth, low squamous cell carcinoma antigen levels, and without osteosarcopenia. Osteosarcopenia was independently correlated with the histopathologic response to NACRT. No significant differences in overall or relapse-free survival were observed based on osteosarcopenia status.

Conclusion: Osteosarcopenia may predict NACRT response in esophageal cancer.

查看原文本刊更多论文

食管癌新辅助放化疗组织病理反应的骨少症预测指标：一项回顾性队列研究。

目的：预测食管癌的放化疗（CRT）反应是必要的，因为患者的预后各不相同。本研究旨在评估骨质减少症对新辅助CRT （NACRT）有效性的影响。方法：纳入95例晚期食管癌nacrt术后行手术切除的患者。采用nacrt前骨骼肌指数和L3、Th11水平骨密度测定骨骼肌减少症和骨质减少症。根据骨骼肌减少症的状态对患者进行分类。结果：37例（39%）患者出现骨骼肌减少症。在肿瘤中，49例（51.6%）为1级（无应答），12例（12.6%）为2级，34例（35.8%）为3级（应答）。NACRT在体重指数高于中位数、肿瘤深度较浅、鳞状细胞癌抗原水平较低、无骨骼肌减少症的患者中更有效。骨骼肌减少症与NACRT的组织病理反应独立相关。基于骨骼肌减少状态的总生存率或无复发生存率无显著差异。结论：骨骼肌减少症可预测食管癌患者的NACRT反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Langenbeck's Archives of Surgery 医学-外科

CiteScore

3.30

自引率

8.70%

发文量

342

审稿时长

4-8 weeks

期刊介绍： Langenbeck''s Archives of Surgery aims to publish the best results in the field of clinical surgery and basic surgical research. The main focus is on providing the highest level of clinical research and clinically relevant basic research. The journal, published exclusively in English, will provide an international discussion forum for the controlled results of clinical surgery. The majority of published contributions will be original articles reporting on clinical data from general and visceral surgery, while endocrine surgery will also be covered. Papers on basic surgical principles from the fields of traumatology, vascular and thoracic surgery are also welcome. Evidence-based medicine is an important criterion for the acceptance of papers.